Cheng‐Yu Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheng‐Yu Chung has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
John F. Cipollo
Division of Bacterial, Parasitic and Allergenic Products (DBPAP), Laboratory for Bacterial Polysaccharides, Center for Biologics Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA
2 shared publications- Michael Betenbaugh
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore Maryland USA
2 shared publications - Qiong Wang
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland
2 shared publications - Shuang Yang
Center for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou, China
2 shared publications Hongpeng Jia
Division of Pediatric Surgery, Department of Surgery Johns Hopkins University Baltimore Maryland USA
1 shared publicationJoseph P. Balthasar
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York
1 shared publication
Latest Publications
- 13 October 2021
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (1) , 102-117
The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions
The N‐glycan pattern of an IgG antibody, attached at a conserved site within the fragment crystallizable (Fc) region, is a critical antibody quality attribute whose structural variability can also impact antibody function. For tailoring the Fc glycoprofile, glycoengineering in cell lines as well as Fc amino acid mutations have been applied. Multiple glycoengineered Chinese hamster ovary cell lines were generated, including defucosylated (FUT8KO), α‐2,6‐sialylated (ST6KI), and defucosylated α‐2,6‐sialylated (FUT8KOST6KI), expressing either a wild‐type anti‐CD20 IgG (WT) or phenylalanine to alanine (F241A) mutant. Matrix‐assisted laser desorption ionization‐time of flight mass spectrometry characterization of antibody N‐glycans revealed that the F241A mutation significantly increased galactosylation and sialylation content and glycan branching. Furthermore, overexpression of recombinant human α‐2,6‐sialyltransferase resulted in a predominance of α‐2,6‐sialylation rather than α‐2,3‐sialylation for both WT and heavily sialylated F241A antibody N‐glycans. Interestingly, knocking out α‐1,6‐fucosyltransferase (FUT8KO), which removed core fucose, lowered the content of N‐glycans with terminal Gal and increased levels of terminal GlcNAc and Man5 groups on WT antibody. Further complement‐dependent cytotoxicity (CDC) analysis revealed that, regardless of the production cells, WT antibody samples have higher cytotoxic CDC activity with more exposed Gal residues compared to their individual F241A mutants. However, the FUT8KO WT antibody, with a large fraction of bi‐GlcNAc structures (G0), displayed the lowest CDC activity of all WT antibody samples. Furthermore, for the F241A mutants, a higher CDC activity was observed for α‐2,6‐ compared to α‐2,3‐sialylation. Antibody‐dependent cellular cytotoxicity (ADCC) analysis revealed that the defucosylated WT and F241A mutants showed enhanced in vitro ADCC performance compared to their fucosylated counterparts, with the defucosylated WT antibodies displaying the highest overall ADCC activity, regardless of sialic acid substitution. Moreover, the FcγRIIIA receptor binding by antibodies did not always correspond directly with ADCC result. This study demonstrates that glycoengineering and protein engineering can both promote and inhibit antibody effector functions and represent practical approaches for varying glycan composition and functionalities during antibody development.
- 13 October 2021
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (1) , 102-117
The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions
The N‐glycan pattern of an IgG antibody, attached at a conserved site within the fragment crystallizable (Fc) region, is a critical antibody quality attribute whose structural variability can also impact antibody function. For tailoring the Fc glycoprofile, glycoengineering in cell lines as well as Fc amino acid mutations have been applied. Multiple glycoengineered Chinese hamster ovary cell lines were generated, including defucosylated (FUT8KO), α‐2,6‐sialylated (ST6KI), and defucosylated α‐2,6‐sialylated (FUT8KOST6KI), expressing either a wild‐type anti‐CD20 IgG (WT) or phenylalanine to alanine (F241A) mutant. Matrix‐assisted laser desorption ionization‐time of flight mass spectrometry characterization of antibody N‐glycans revealed that the F241A mutation significantly increased galactosylation and sialylation content and glycan branching. Furthermore, overexpression of recombinant human α‐2,6‐sialyltransferase resulted in a predominance of α‐2,6‐sialylation rather than α‐2,3‐sialylation for both WT and heavily sialylated F241A antibody N‐glycans. Interestingly, knocking out α‐1,6‐fucosyltransferase (FUT8KO), which removed core fucose, lowered the content of N‐glycans with terminal Gal and increased levels of terminal GlcNAc and Man5 groups on WT antibody. Further complement‐dependent cytotoxicity (CDC) analysis revealed that, regardless of the production cells, WT antibody samples have higher cytotoxic CDC activity with more exposed Gal residues compared to their individual F241A mutants. However, the FUT8KO WT antibody, with a large fraction of bi‐GlcNAc structures (G0), displayed the lowest CDC activity of all WT antibody samples. Furthermore, for the F241A mutants, a higher CDC activity was observed for α‐2,6‐ compared to α‐2,3‐sialylation. Antibody‐dependent cellular cytotoxicity (ADCC) analysis revealed that the defucosylated WT and F241A mutants showed enhanced in vitro ADCC performance compared to their fucosylated counterparts, with the defucosylated WT antibodies displaying the highest overall ADCC activity, regardless of sialic acid substitution. Moreover, the FcγRIIIA receptor binding by antibodies did not always correspond directly with ADCC result. This study demonstrates that glycoengineering and protein engineering can both promote and inhibit antibody effector functions and represent practical approaches for varying glycan composition and functionalities during antibody development.
- 23 September 2019
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (1) , 157-166
The impact of sialylation linkage‐type on the pharmacokinetics of recombinant butyrylcholinesterases
Chinese Hamster Ovary (CHO) cells typically produce glycoproteins with N‐glycans terminating in α‐2,3 sialylation. Human cells produce glycoproteins that include α‐2,3 and α‐2,6 sialic acids. In order to examine the impact of altering protein sialylation on pharmacokinetic properties, recombinant human butyrylcholinesterase (BChE) was produced in CHO cells by knocking out the α‐2,3 sialyltransferase genes followed by overexpression of the α‐2,6 sialyltransferase (26BChE) enzyme. The N‐glycan composition of 26BChE was compared to BChE with α‐2,3 sialylation (23BChE) derived from wild‐type CHO cells. Both 23BChE and 26BChE exhibited comparable antennarity distributions with bi‐antennary di‐sialylated glycans representing the most abundant glycoform. CD‐1 mice were intravenously injected with the 23BChE or 26BChE, and residual BChE activities from blood collected at various time points for pharmacokinetic analyses. Although 23BChE contained a slightly lower initial sialylation level compared to 26BChE, the molecule exhibited higher residual activity between 5 to 24 hours post‐injection. Pharmacokinetic analyses indicated that 23BChE exhibited an increase in area under the curve (AUC) and a lower volume of distribution at steady‐state than that of 26BChE. These findings suggest that the type of sialylation linkage may play a significant role in the pharmacokinetic behavior of a biotherapeutic when tested in in vivo animal models.
- 23 September 2019
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (1) , 157-166
The impact of sialylation linkage‐type on the pharmacokinetics of recombinant butyrylcholinesterases
Chinese Hamster Ovary (CHO) cells typically produce glycoproteins with N‐glycans terminating in α‐2,3 sialylation. Human cells produce glycoproteins that include α‐2,3 and α‐2,6 sialic acids. In order to examine the impact of altering protein sialylation on pharmacokinetic properties, recombinant human butyrylcholinesterase (BChE) was produced in CHO cells by knocking out the α‐2,3 sialyltransferase genes followed by overexpression of the α‐2,6 sialyltransferase (26BChE) enzyme. The N‐glycan composition of 26BChE was compared to BChE with α‐2,3 sialylation (23BChE) derived from wild‐type CHO cells. Both 23BChE and 26BChE exhibited comparable antennarity distributions with bi‐antennary di‐sialylated glycans representing the most abundant glycoform. CD‐1 mice were intravenously injected with the 23BChE or 26BChE, and residual BChE activities from blood collected at various time points for pharmacokinetic analyses. Although 23BChE contained a slightly lower initial sialylation level compared to 26BChE, the molecule exhibited higher residual activity between 5 to 24 hours post‐injection. Pharmacokinetic analyses indicated that 23BChE exhibited an increase in area under the curve (AUC) and a lower volume of distribution at steady‐state than that of 26BChE. These findings suggest that the type of sialylation linkage may play a significant role in the pharmacokinetic behavior of a biotherapeutic when tested in in vivo animal models.